Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cardinal Health to acquire Harvard Drug for $1.12bn

This article was originally published in Scrip

Executive Summary

Cardinal Health (Dublin, Ohio) is to acquire The Harvard Drug Group (THDG; Livonia, Michigan), a distributor of generic pharmaceuticals, over-the-counter medications and related products, for $1.12bn using cash and debt. THDG is currently owned by Court Square Capital Partners. The transaction, which is slated to close at the start of fiscal year 2016, would add about $0.15 per share to its earnings, said Cardinal Health. As a result of this planned acquisition and the pending acquisition of Cordis, Cardinal Health expects EPS of around $4.75 to $5.05 in fiscal 2016. THDG had revenues of approximately $450m in 2014. There are 450 employees and two distribution facilities included in the transaction.

You may also be interested in...

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer

Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts